Shilpa Medicare Limited · NSE:SHILPAMED
Shilpa Medicare — Q3 FY22 Earnings Presentation
26 slides from Shilpa Medicare's earnings presentation, Feb 10, 2022
Slide 1: Cover letter to stock exchanges: Investor Presentation Q3 FY22
Shilpa Medicare Limited Corporate & Admin Office: “Shilpa House”, # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com CIN: L85110KA1987PLC008739 10 February 2022 Corporate Relationship Departme
Slide 2: Shilpa Medicare Limited Q3 FY22 Results Presentation
Shilpa Medicare Limited (SML) Q3 FY22 Results Presentation 1
Slide 3: Disclaimer
2 Disclaimer Certain statements in this document may be forward-looking statements. Such forward looking statements are subject to certain risks and uncertainties like regulatory changes, local political API Units, Raichur or economic developments, and many other factors that could cause our actual
Slide 4: Company Overview
Company Overview 3 Pursuing niche growth businesses like Biologics, Transdermal & Oral Dissolving Films Formulations Established presence in Active Pharmaceutical Ingredients (APIs) and Formulations for Affordable & Robust research domestic & international markets Effective orientation resulting in
Slide 5: Table of Contents
Table of Contents 4 Financial Performance........................................05 Discussion on APIs/Formulations/New Segments……09/15/19 Other Updates.................................................21
Slide 6: Financial Performance
Financial Performance 5
Slide 7: Abridged P&L Statement - Consolidated
Abridged P&L Statement - Consolidated 6 (Rs. In Lakhs) Particulars Q3 Y22 Q3 FY21 Change (%) 9M FY22 9M FY21 Change (%) Total Income (I+II) 27,778 19,986 39 81,368 71,634 14 I. Total Revenue from Operations (A+B+C+D) 27,230 19,125 42 80,493 69,305 16 •API (A) 18,195 13,533 34 50,216 46,128 9 •Formul
Slide 8: Abridged P&L Statement - Standalone
Abridged P&L Statement - Standalone 7 (Rs. In Lakhs) Particulars Q3 FY22 Q3 FY21 Change (%) 9M FY22 9M FY21 Change (%) Total Income (I+II) 28,964 17,990 61 83,476 66,938 25 I. Total Revenue from Operations 27,664 17,129 62 80,284 65,061 23 (A+B+C+D) •API (A) 18,195 12,782 42 50,216 43,998 14 •Formul
Slide 9: Managing Director's Message
Managing Director’s Message 8 Commenting on Q3 FY’22 performance, Mr.Vishnukant Bhutada, Managing Director Shilpa Medicare Limited said, ““Momentum in API business continues to improve in line with the measures we have taken, which is heartening. We have a deep pipeline of products that will help us
Slide 10: Discussion of API Segment
Discussion of API Segment 9
Slide 11: Perspectives on APIs
Perspectives on APIs 10 Key strengths of the business • Wide range of Oncology & Non oncology niche product portfolio • Building capacity & capability to improve efficiency & reach • Continuous improvement in process, operation & development to improve the yield , quality & compliance to maintain le
Slide 12: API Revenue Highlights
11 API REVENUE HIGHLIGHTS Rs. In Lakhs 12,000 10,000 8,000 6,000 4,000 2,000 - Oncology Non-Oncology Crams Q2 FY22 11,352 4,730 2,972 Q3FY22 10,679 5,112 2,403 Q3 FY21 7,423 2,367 2,992
Slide 13: Product wise DMF filings as on December 31, 2021
Product wise DMF filings as on December 31, 2021 12 TGA & KFDA GCC WHO Name of the API US FDA EU/ EMEA TPD-Canada PMDA Japan EDQM Medsafe-NZ Korea & ROW Market Ambroxol HCl Azacitidine Bicalutamide Bendamustine HCl Bortezomib Busulfan
Slide 14: Product wise DMF filings as on December 31, 2021
Product wise DMF filings as on December 31, 2021 13 TGA & KFDA GCC WHO Name of the API US FDA EU/ EMEA TPD-Canada PMDA Japan EDQM Medsafe-NZ Korea & ROW Market Clofarabine Dimethyl Fumarate Axitinib Enzalutamide Pirfenidone Gemcitabine Hydrochloride (Process-2) Ibruti
Slide 15: Product wise DMF filings as on December 31, 2021
Product wise DMF filings as on December 31, 2021 14 TGA & KFDA GCC WHO Name of the API US FDA EU/ EMEA TPD-Canada PMDA Japan EDQM Medsafe-NZ Korea & ROW Market Nifedipine Phenylephrine hydrochloride Nilotinib Varenicline tartrate Cabazitaxel Glycopyrronium bromide
Slide 16: Discussion of Formulations Segment
Discussion of Formulations Segment 15
Slide 17: Perspectives on Formulations
Perspectives on Formulations 16 Key strengths of the business • Vertically integrated backed by in-house R&D and innovative APIs with sharp cost competencies • Range includes liquid and lyophilized injectable, sterile dry powder injections and oral solids in onco & adjuvant therapies • Strong portfo
Slide 18: Formulation - Highlights
Formulation - Highlights 17 Revenue Split (Rs. In Lakhs) Q3 FY22 210 , 3% Q2 FY22 Q3 FY21 50 , 1% 450 , 5% 377 , 4% 91 , 2% 21 , 1% 427 , 2,246 , USA' USA' 12% 3,220 , USA' 27% EUROPE 37% EUROPE EUROPE ROW ROW ROW 5,529 , DOMESTIC 4,925 , DOMESTIC 56% 2,969 , DOMESTIC 67% 85% Rs. 8,276 Rs. 8,732 Rs.
Slide 19: Formulation Product Pipeline as on December 31, 2021
Formulation Product Pipeline as on December 31, 2021 18 Regulatory Approved Filings Pending Submissions (Including Tentative) - US ANDA: SML 26 13 13 - US NDA: SML 03 01 02 - US ANDA: Customers 18 13 05 TOTAL (In US) 47 27 20 - EU Filing 25 19 06 - Row Filling 279 95 184 TOTAL (In EU & ROW) 304 114
Slide 20: Discussion of Biologicals
Discussion of Biologicals 19
Slide 21: Perspectives on Biologicals
Perspectives on Formulations 20 Key strengths of the business • Strong R&D with focus on difficult products • World class manufacturing facility • Development of 1 NBE and 6 biosimilars in limited competition space with significant cost advantage • 2 products in human clinical & 1 in animal clinical
Slide 22: Other Updates
Other Updates 21
Slide 23: Patents Status as on December 31, 2021
Patents Status as on December 31, 2021 22 Patents Filings Granted Pending - API 208 45 163 - Formulation* 182 35 147 - Films Topical & Transdermal 61 6 55 - Biologicals 12 5 7 - Others 22 5 17 TOTAL 485 96 389 * Formulation numbers includes the Patents of FTF Pharma Pvt Ltd Ahmedabad, a wholly owned
Slide 24: Manufacturing Excellence
Manufacturing Excellence 23 Dharwad Jadcherla Unit • Formulations (Onco & Adjuvant • Biologicals Manufacturing plant & Therapy R&D Facility • of Onco – Injectable & Oral) Bengaluru Unit Hyderabad • Formulations (Oral Dissolving Films) • TDS & ODF Manufacturing Facility • Bio Analytical Lab, & Formul
Slide 25: About Shilpa Medicare Ltd.
About Shilpa Medicare Ltd. 24 Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1989 at Raichur, Karnataka- India. Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of affordable API and Formulation globally in different regulated marke
Slide 26: Thank You
25 Thank You